Document:

Exhibit
10.29

 

Appendix
2

 

Agreement

 

between

 

N.
N.

D.O.B.
[...]

resident in [...]

-
hereinafter also referred to as “BENEFICIARY” -

 

and

 

CureVac
AG,

Paul-Ehrlich-Straße
15, 72076 Tübingen

-
hereinafter also referred to as “CUREVAC” -

 

-
THE BENEFICIARY AND CUREVAC ALSO HEREINAFTER JOINTLY REFERRED TO AS “PARTIES” -

 

     

     

    

 

Preliminary
Remarks

 

The
BENEFICIARY has concluded a contract with the legal predecessor of CUREVAC, CureVac GmbH, on [...] [and where applicable on
[...]] to participate in the employee participation pro-gram (hereinafter referred to as “VAP”; the above
jointly (including all supplements) referred to as “VAP CONTRACT”). The VAP contract has gaps and inaccuracies
that are now to be filled or specified.

 

With
this in mind, the following is agreed:

 

CUREVAC
and the BENEFICIARY agree that the VAP CONTRACT has gaps in the rules that are to be closed with the present agreement while maintaining
all claims already acquired by the beneficiaries from the VAP CONTRACT. As part of this, the VAP CONTRACT is to be supple-mented
with an “IPO” exercise case in accordance with the original intention of the program and thus adapted to the current
development at the CUREVAC level.

 

    2 

     

    

 

CUREVAC
and the BENEFICIARY therefore agree to amend the VAP CONTRACT, which now reads as follows:

 

Contract
on Participation in the Employee Participation Program

 

	Section
1	-	Allocation
                                         of Participation Points

 

		(1)	CUREVAC
                                         has granted the BENFICIARY a total of [...] PARTICIPATION POINTS (the “PARTICIPATION
                                         POINTS”) free of charge . For [...] PARTICIPATION POINTS, the [...]
                                         is the day of the allocation (“DATE OF THE ALLOCATION”); for [...] PARTICIPA-TION
                                         POINTS, the [...] is the DATE OF THE ALLOCATION.

 

		(2)	The
                                         PARTICIPATION POINTS are granted on the basis of the provisions set out in this contract.

 

		(3)	Each
                                         PARTICIPATION POINT exclusively constitutes the right of the BENEFICIARY to a payment
                                         in the share deal exercise case within the meaning of Section 8 or in the merger/asset
                                         deal exercise case within the meaning of Section 9 or to payment or provision of shares
                                         in the IPO exercise case within the meaning of Section 5 or in the merger/asset deal
                                         exercise case within the meaning of Section 9 of this contract and is used as the assessment
                                         basis for calculating the amount of the payment to be made or the number of shares to
                                         be granted .

 

		(4)	Beyond
                                         the exercise of the IPO within the meaning of Section 5 of this contract, this contract
                                         does not at any time establish a claim to the provision of shares in CUREVAC. The BENEFICIARY
                                         is not entitled to dividends or other payments from shares in CUREVAC.

 

		(5)	The
                                         allocation of the PARTICIPATION POINTS was made based on the free choice of CUREVAC,
                                         which is at the company’s own discretion. CUREVAC is not obliged to grant further PARTICIPATION
                                         POINTS, even if the PARTICIPATION POINTS have been granted several times.

 

		(6)	This
                                         contract has no effect on the calculation of bonus payments, royalties, pension plans
                                         or other remuneration of the BENEFICIARY by CUREVAC. The VAP does not serve to compensate
                                         the work performed by the BENEFICIARY for CUREVAC.

 

    3 

     

    

 

		(7)	ureVac
                                         and the BENEFICIARY agree that CUREVAC undertakes to pay the BENEFI-CIARY as holder of
                                         PARTICIPATION POINTS - depending on the type of exercise - in connection with the VAP
                                         a total of no more than the number of shares, which cor-responds to a maximum of the
                                         total of the PARTICIPATION POINTS allotted to the BENEFICIARY, or to pay an amount corresponding
                                         to the sale value of these shares at the time of the exercise. Any further use of CUREVAC
                                         from and in connection with the VAP is excluded.

 

	Section
2	-	Vestability

 

 

		(1)	The
                                         PARTICIPATION POINTS granted, including all associated rights, are subject to the subsequent
                                         condition (the “EXPIRY”).

 

 

		(2)	The
                                         vestability of the PARTICIPATION POINTS granted on the allocation date of [...] arises
                                         in a period of 60 (sixty) months, while the vestability of PARTICIPATION POINTS granted
                                         on the allocation date of [...] ARISES IN A PERIOD OF [...] months (“VESTABILITY
                                         PERIOD”). The vesting period begins on the allocation date. In the vest-ing
                                         period, one-sixtieth of the total number of PARTICIPATION POINTS granted in the allocation
                                         letter - calculated from the allocation date - expires after the end of each month (the
                                         “VESTABILITY”). The remaining PARTICIPATION POINTS are subject to expiry.

  

		(3)	The
                                         term of the vestability period is inhibited (pursuant to Section 209 BGB) for the period
                                         of an absence of the BENEFICIARY due to parental leave or due to illness, starting on
                                         the day from which the right to continued payment based on the corre-sponding employment
                                         contract ends. The same applies to the times in which the BEN-EFICIARY was temporarily
                                         released from his contractual obligations (unpaid leave, leave for further training,
                                         etc.).

 

		(4)	If
                                         the inhibition of the vesting period in accordance with Section 2 (3) exceeds half the
                                         period until the vesting period in accordance with (2), all rights and obligations from
                                         this contract expire. There is an exception for PARTICIPATION POINTS that are vested
                                         at this time in accordance with Section 2 (6).

 

		(5)	The
                                         condition subsequent according to (1) occurs in the cases mentioned in a) and b) below,

 

    4 

     

    

 

		a)	if
                                         (i) the employment of the BENEFICIARY at CUREVAC (the “EMPLOYMENT”)
                                         is terminated for an important reason for which the BENEFICIARY is not responsi-ble (e.g.
                                         criminal acts against CUREVAC), or other reasons not covered by b) be-low (the “BAD
                                         LEAVER”) or (ii) enforcement is carried out on the assets of the BENEFICIARY
                                         on the basis of a title that is not merely provisionally enforceable and the seizure
                                         is not removed within two months or insolvency proceedings are opened on the assets of
                                         the BENEFICIARY or (iii) the opening of these proceed-ings is refused due to lack of
                                         assets. The above also applies in the event that the vesting period has already expired
                                         at this point.

 

		b)	if
                                         the employment contract ends during the vesting period due to

 

		(i)	disability
                                         of the BENEFICIARY,

 

		(ii)	termination
                                         by CUREVAC without cause;

 

		(iii)	the
                                         BENEFICIARY’s retirement,

 

		(iv)	death
                                         of the BENEFICIARY, or

 

	 	(v)  
                                         	ordinary
                                         termination of the employment contract by the BENEFI-CIARY, the requirements of which
                                         are objectively verifiable, (the “GOOD LEAVER”). In this case, the condition
                                         subsequent only applies to the part of the PARTICIPATION POINTS that are subject to expiry
                                         in accordance with the procedure set out in Section 2 (2).

  

		(6)	The
                                         PARTICIPATION POINTS which are no longer subject to expiry in accordance with paragraphs
                                         (2) and (3) above and which the BENEFICIARY is entitled to after application of paragraph
                                         (5) above are “vestable PARTICIPATION POINTS” (the “VESTABLE PARTICIPATION
                                         POINTS”). The number of vestable PARTICIPATION POINTS is used to calculate the
                                         amount of the payment entitlement or to calculate the number of shares to be transferred,
                                         to which the BENEFICIARY is entitled when the an exercise occurs.

 

		(7)	In
                                         order to avoid misunderstandings, it is clarified between the parties that the BEN-EFICIARY
                                         is not entitled to claim any cash payment or reimbursement with regard to the PARTICIPATION
                                         POINTS for which the condition subsequent has been met and/or has no other claims of
                                         any kind.

 

    5 

     

    

 

	Section
3	-	Transferability

 

		(1)	The
                                         transfer of PARTICIPATION POINTS is excluded (ban on disposal). The same applies to all
                                         legal transactions comparable to such transfers , such as the granting of sub-participations,
                                         straw man participations, repurchase agreements (e.g. the estab-lishment of so-called
                                         short positions)and any comparable measures.

 

		(2)	In
                                         the event of a violation of the ban on disposal pursuant to (1), all rights to PARTIC-IPATION
                                         POINTS acquired under this contract expire, including the vestable PAR-TICIPATION POINTS
                                         (condition subsequent pursuant to Section 158 (2) BGB).

 

		(3)	Deviating
                                         from paragraph (1), the transfer of vested PARTICIPATION POINTS due to death is possible.
                                         The heirs and/or legatees are obliged to legitimise themselves by presenting a certificate
                                         of inheritance to CUREVAC.

 

		(4)	If
                                         the claims referred to in (3) are shared by several heirs and/or legatees, the heirs
                                         and/or legatees are obliged to appoint a proxy for the exercise of their rights to exer-cise
                                         their rights jointly. In this case, the exercise of rights by individual heirs and/or
                                         legatees is not permitted. All rights of the heirs and/or legatees with the exception
                                         of the rights according to Sections 4 to 11 remain dormant until the appointment of a
                                         proxy; payments of or transfer of shares by CUREVAC to the heirs and/or legatees are
                                         only to be made to the proxy.

 

	Section
4 	-	Amount
                                         of the Beneficiary’s Claims

 

		(1)	The
                                         amount of the rights of the BENEFICIARY according to the following Sections 5, 8 and
                                         9 (the “SHARE OF THE REVENUE”) is determined according to the virtual
                                         propor-tional participation of the BENEFICIARY in the share capital of CUREVAC at the
                                         time of occurrence of one the exercise cases specified in this contract (the “EXERCISE
                                         CASE”). The virtual proportional participation of the BENEFICIARY corresponds
                                         to the participation that the BENEFICIARY would have been granted in the case of an actual
                                         non-privileged participation in the share capital of CUREVAC according to the VESTA-BLE
                                         PARTICIPATION POINTSof the BENEFICIARY. In the share deal exercise case, the BENEFICIARY
                                         is therefore, for example, positioned as if he had (also) sold NON-VESTED PARTICIPATION
                                         POINTS in connection with an exercise case in the same ratio as the CUREVAC shareholders.

 

    6 

     

    

 

		(2)	When
                                         this contract is signed, a vested participation point arithmetically (virtually) cor-responds
                                         to a nominal amount of one euro in the share capital of CUREVAC, but as a non-privileged
                                         shareholder who does not enjoy any special rights, e.g. on liquidation preference.

 

		(3)	In
                                         case of doubt, the principles set out in this Section 4 take precedence over the regulations
                                         in Sections 5, 8 and 9, including Appendices 1 - 4.

 

	Section
5	-	IPO
                            Exercise Case

 

		(1)	The
                                         IPO exercise case is given, if, within the term of the VAP, the requirements under a) 
                                         and b) are met cumulatively and if also during the listing of CUREVAC one of the requirements
                                         under c), d) and/or e) are alternatively fulfilled:

 

		a)	the
                                         shares of CUREVAC are admitted to a domestic or foreign stock exchange and then integrated
                                         into stock exchange trading (“INITIAL LISTING”),

 

		b)	the
                                         lock-up periods resulting from the relevant stock exchange listing provisions and the
                                         agreements made with the underwriters have expired,

 

		c)	a
                                         shareholder who, at the time of the conclusion of this agreement, holds more than 50%
                                         of the shares in CUREVAC or its legal successor (hereinafter also re-ferred to as “MAJORITY
                                         SHAREHOLDER”), sells, after the date of the initial listing of CUREVAC shares
                                         on the stock exchange as defined in a) (hereinafter also referred to as “TIME
                                         OF THE INITIAL LISTING”), cumulatively to one or more third parties not affiliated
                                         with the majority shareholder within the meaning of Section 15 AktG since the date of
                                         the initial listing, a total of at least 5% of the shares held by the majority shareholder
                                         at the time of the initial listing (the reaching of this threshold is also referred to
                                         as “SHARE SALE AFTER IPO”). After the start of a share sale after the
                                         IPO, the regulation of the previous sentence applies accordingly for every further transaction
                                         by majority shareholders and regardless of the number of shares sold by them (this case
                                         or cases are also referred to as “FURTHER SHARE SALE AFTER IPO”),

 

		d)	an
                                         active ingredient of CUREVAC or another substance developed by CUREVAC for human therapy
                                         is approved as a drug by a competent authority in the United States or Europe for the
                                         market as a non-conditional approval (this case is also referred to as “DRUG
                                         APPROVAL AFTER IPO”),

 

    7 

     

    

 

		e)	there
                                         is sufficient liquidity in the share. Sufficient liquidity is available if, after the
                                         time of the initial listing, the following requirements (i) and (ii) are met cumulatively
                                         at the end of the subsequent 12-month period (“12-MONTH PERIOD”) (this
                                         case is also referred to as “LIQUIDITY AFTER IPO”); a separate analysis
                                         is carried out for each 12-month period:

 

		(i)	the
                                         weighted average turnover of CUREVAC shares within the relevant 12-month period exceeds
                                         five times the number of shares of CUREVAC in free float during this 12-month period
                                         (as defined in (ii) below).

 

		(ii)	the
                                         number of free float shares is at least 10% on average over the relevant 12-month period.
                                         Free float shares are such a number of shares in CUREVAC that are (aa) traded on the
                                         stock exchange and (bb) not held by the former shareholders of CUREVAC or their legal
                                         successors or new shareholders, pro-vided that they participate in a financing round
                                         for the first time before CUREVAC’s initial listing or companies affiliated with it (Section
                                         15 AktG).

 

	 	 	The
                                         exercise of liquidity after the IPO can take place repeatedly in each 12-month period
                                         after the date of the initial listing.
	 	 	 
	 	 	The
                                         restrictions of the above requirements under c), d) and e) for the exercise of the IPO
                                         shall not apply 9 years after the date of the initial listing.
	 	 	 
		(2)	The
                                         BENEFICIARY acquires the right to acquire a certain number of shares in CUREVAC free
                                         of charge from CUREVAC in the exercise of the IPO in accordance with (1). CUREVAC is
                                         entitled to make a cash payment instead of transferring shares. At CureVac’s request,
                                         the BENEFICIARY is obliged to contribute his payment claim in accordance with sentence
                                         2 above as a contribution in kind against the granting of shares in CUREVAC to CUREVAC.

 

		a)	In
                                         the case of a share sale after an IPO or another share sale after an IPO:
	 	 	 
	 	 	The
                                         BENEFICIARY receives a right to transfer shares to CureVac. The claim is limited in this
                                         respect and a maximum of such number of PARTICIPATION POINTS (calculated from the total
                                         number of PARTICIPATION POINTS granted to the BENEFICIARY) may be exercised in terms
                                         of how it corresponds to the ratio of the shares sold by the majority shareholder in
                                         the context of the share sale after the IPO or further share sale after the IPO to the
                                         shares held by the majority shareholder at the time of the initial listing;

 

    8 

     

    

 

Examples:

  

Share
sale after IPO: the majority shareholder holds 1,000 shares at the time of the initial listing and sells 100 shares as part of
the share sale after IPO, i.e. 10% of the shares held by him. 500 PARTICIPATION POINTS were allocated to the BENEFICIARY. Accordingly,
the BENEFICIARY is entitled to 10%, i.e. 50 PAR-TICIPATION POINTS.

 

Further
share sale after IPO: After the share sale after the IPO, the majority shareholder still holds 900 shares and sold 40 shares as
part of a further share sale after the IPO, i.e. 4% of the shares held by him at the time of the initial listing. The BENEFICIARY
is therefore entitled to a further 4% of the PARTICIPATION POINTS originally held by him, i.e. 20 PARTICIPATION POINTS.

 

		b)	In
                                         the case of drug approval after IPO:

 

The
BENEFICIARY receives a right to transfer shares to CUREVAC. 100% of the BENEFICIARY’s PARTICIPATION POINTS can be exercised; only
a partial ex-ercise of the PARTICIPATION POINTS by the BENEFICIARY is excluded.

 

 

		c)	In
                                         the case of liquidity after IPO:

 

The
BENEFICIARY receives a right to transfer shares to CUREVAC. Up to 10% of the PARTICIPATION POINTS granted to the BENEFICIARY can
be exercised in each 12-month period.

 

After
9 years from the time of the initial listing, 100% of the remaining PARTICIPA-TION POINTS of the BENEFICIARY can be exercised;
only a partial exercise of the PARTICIPATION POINTS by the BENEFICIARY is excluded.

 

		(3)	Irrespective
                                         of the existence of the further requirements in accordance with Section 5 (1)  
                                         c) d) or e), the BENEFICIARY receives the right to exercise up to 10% of the vested PARTICIPATION
                                         POINTS granted to the BENEFICIARY if the requirements of Section 5 (1) a) and b) are
                                         met cumulatively. If the company is financed with regard to the initial listing (“CROSS-OVER
                                         FINANCING”) and in connection with the cross-over financing at least 10% of
                                         the shares held by the former shareholders or by legal suc-cessors of the former shareholders
                                         are sold to one or more new investors (“SHARE SALE”), the BENEFICIARY
                                         has the right to exercise up to 10% of the PARTICIPATION POINTS granted to him before
                                         the initial listing and within 7 days after notification of the intended share sale and
                                         to sell the shares thereby acquired in the course of the share sale; the selling former
                                         shareholder of CUREVAC or its legal successor must work towards this co-sale to the respective
                                         third party. If the BENEFICIARY exercises his right under this paragraph (3) sentence
                                         2, the claim under paragraph (3) sentence 1 expires. Paragraph (2) sentences 2 and 3
                                         apply accordingly.

 

    9 

     

    

 

		(4)	The
                                         calculation of the shares to be transferred in the exercise of the IPO to the bene-ficiaries
                                         or the amount of the payment claim existing at CureVac’s discretion is based on Appendix
                                         1.

 

	 	(5)	vIn
                                         the event of capital increases from company funds, with every capital reduction or restructuring
                                         measure, without the requirements of the merger/asset exercise within the meaning of
                                         Section 9 (1) which took place before an exercise being met simulta-neously, the BENEFICIARY’s
                                         claim is to be corrected. This correction (“adjustment”) is based on the principles
                                         outlined in Appendix 4.

 

	Section
6	-	Exercise Declaration
for the IPO Exercise Cases

 

		(1)	CUREVAC
                                         undertakes to notify the BENEFICIARY in writing of the number of shares which the BENEFICIARY
                                         is entitled to transfer in accordance with Section 5 above immediately after the exercise
                                         of an IPO.

 

		(2)	The
                                         BENEFICIARY undertakes to notify CUREVAC in writing within a period of four weeks, starting
                                         with the receipt of this notification according to (1) (hereinafter also referred to
                                         as “EXERCISE WINDOW”), of the amount of PARTICIPATION POINTS he would
                                         like to use, i.e. the number of shares he would like to receive (hereinafter also referred
                                         to as “EXERCISE DECLARATION”). CUREVAC must receive this exercise decla-ration,
                                         which is binding for the BENEFICIARY, within the exercise window. CUREVAC is entitled
                                         to reject exercise declarations that have not been completed in full. If and insofar
                                         as the BENEFICIARY does not exercise the right to exercise the IPO in the exercise case
                                         by submitting the exercise declaration within the exercise window, this irrevocably expires.

 

    10 

     

    

 

		(3)	The
                                         transfer of the shares or the corresponding payment to the BENEFICIARY takes place immediately
                                         after the exercise window has ended. Both CUREVAC and the BEN-EFICIARY are obliged to
                                         participate in all measures necessary to transfer the shares, to take action and to make
                                         declarations.

 

	Section
7	- 	Limitations on Disposal
during an IPO Exercise, Insider Information

 

The
BENEFICIARY is advised that, as an employee or organ of CUREVAC, he belongs to the group of people who, as insiders within the
meaning of Article 8 ff., may have so-called inside information relating to CUREVAC in terms of the Market Abuse Ordinance as
amended as well as corresponding foreign regulations that may apply. The BENEFICIARY is further advised that, among other things,
the purchase and sale of shares in CUREVAC are punishable if they are aware of insider circumstances.

 

	Section
8	-	Share Deal Exercise
Case

 

		(1)	The
                                         share sale exercise case exists if, within the term of the VAP according to Section 13
                                         (1), the following requirements are cumulatively met:

 

		a)	CUREVAC
                                         is not listed on the stock exchange at the time of the occurrence of the requirements
                                         according to b) and c).

 

		b)	At
                                         least 50% of all CUREVAC shares (with and without preferential rights) are sold to one
                                         or more independent third parties in a single transaction or multiple related transactions.
                                         Multiple transactions are considered to be contiguous within the meaning of sentence1
                                         if they take place within 12 months, the date of the respec-tive conclusion of the contract
                                         for sale being decisive. For the measurement of the threshold of fifty percent, in the
                                         case of related transactions, the last transac-tion in the period according to sentence
                                         2 must be used.

 

		c)	The
                                         consideration owed by the independent third party/parties for the acquisition of the
                                         SHARES in CUREVAC has been rendered and is finally at the free disposal of the selling
                                         shareholders. In the case of milestone payments, the BENEFI-CIARY receives the payments
                                         like the selling shareholders, i.e. then , when the milestones are paid. The payment
                                         to the BENEFICIARY must be made 4 weeks after the respective selling shareholders have
                                         received the respective milestone payment.

 

    11 

     

    

 

A
third party is independent within the meaning of this paragraph (1) if it is not one or more persons or companies associated with
CUREVAC or the shareholders of CUREVAC (also jointly) within the meaning of Section 15 AktG.

 

		d)	The
                                         consideration agreed for the purchase of the SHARES in CUREVAC, calculated on all SHARES
                                         IN CUREVAC, amounts to at least EUR 357,188,892.00.

 

		(2)	In
                                         the exercise of a share deal in accordance with paragraph (1), the BENEFICIARY is entitled
                                         to a sharein the revenue from CUREVAC, which is to be paid in the form of cash. The amount
                                         of this share in the revenue is calculated in accordance with the principles set out
                                         in Appendix 2 for the share deal exercise.

 

		(3)	In
                                         the event of capital increases from company funds or of any capitalreduction or restructuring
                                         measures, without simultaneously meeting the requirements of the mer-ger exercise within
                                         the meaning of Section 9 (1), which took place after the signing of this contract and
                                         before the exercise, the BENEFICIARY’s claim is to be corrected in accordance with paragraph
                                         (2). This correction (the “ADJUSTMENT”) is based on the principles set
                                         out in Appendix 4.

 

	Section
9	- 	Merger/Asset Deal
Exercise Case

  

		(1)	The
                                         merger/asset deal exercise case exists if, within the term of the VAP , the follow-ing
                                         requirements are cumulatively met:

 

		a)	In
                                         a single transaction or multiple related transactions, all shares in CUREVAC or more
                                         than 50% of CureVac’s assets are transferred to one or more independent parties, for
                                         example as part of (i) a merger within the meaning of the Transfor-mation Act as amended,
                                         (ii) a spin-off, (iii) a transfer to another company as a contribution in kind, , (iv)
                                         a sale of the assets or (v) another economically compa-rable measure . Multiple transactions
                                         within the meaning of sentence 1 are con-sidered to be contiguous if they take place
                                         within 12 months, where the date of the conclusion of this contract is decisive. For
                                         the measurement of the threshold of fifty percent, in the case of related transactions,
                                         the last transaction in the pe-riod according to sentence 3 must be used.

 

    12 

     

    

 

 

		b)	In
                                         return, the shareholders of CUREVAC
                                         or CUREVAC
                                         itself receive shares in the other independent company and/or (ii) a cash payment.
                                         The agreed considera-tion, calculated on all shares in CUREVAC,
                                         amounts to at least EUR 357,188,892.00.

 

The
shareholders or CureVac have received the consideration within the mean-ing of the preceding sentence if this is finally at the
free disposal of CUREVAC
or its shareholders.

  

A
third party is independent within the meaning of this paragraph (1) if it is not one or more people affiliated with CUREVAC
or with CUREVAC shareholders (also jointly) within
the meaning of Section 15 AktG or companies.

  

		(2)	In
                                         the exercise of a merger/asset deal in accordance with paragraph (1), the BENE-FICIARY
                                         is entitled to a share in the revenue from CUREVAC,
                                         which is in the form of money or, if the consideration to CUREVAC
                                         consists in the granting of shares in a company, in the payment of shares, provided
                                         these are admitted to trading on a do-mestic or foreign stock exchange, failing which
                                         it must be settled in cash. The calcu-lation of the amount of the share in the revenue
                                         is based on the principles set out in Appendix 3 for the merger/asset deal exercise.

  

		(3)	In
                                         the event of capital increases from company funds or any capital reduction or re-structuring
                                         measures that have taken place since the signing of this contract and be-fore the exercise,
                                         the claim of the BENEFICIARY must be corrected in accordance with paragraph (2). This
                                         correction (the "ADJUSTMENT") is
                                         based on the principles out-lined in Appendix 4.

 

	Section
    10	-	Assertion
    of the Claim of the Beneficiary in the

 

Share
Deal and Merger/Asset Deal Exercise Cases, Type of Performance

  

The
entitlement of the BENEFICIARY in the share deal and merger/asset deal exer-cise casesmust be satisfied within 4 weeks of the
occurrence of the last requirement of the respective exercise case. When agreeing milestone payments, Section 8 (1) c sentence
2 and 3 shall apply. The amount of money owed is to be paid into a bank account to be named by the BENEFICIARY to CUREVAC.
Shares owed are to be transferred to a securities account of the BENEFICIARY.

  

    13 

     

    

 

	Section
    11	- 	Compensation
    Claim, Final Settlement

  

		(1)	In
                                         the event that the employment of the BENEFICIARY ends during the term of the VAP and
                                         within the period specified in Section 2 (2) plus the period in which there was an inhibition
                                         pursuant to Section 2 (3) and the BENEFICIARY, according to Section 2 (6), is already
                                         entitled to vested PARTICIPATION POINTS and no exercise occurred within twenty-four months
                                         after the end of employment, CUREVAC is entitled to settle all claims of the BENEFICIARY
                                         in connection with this contract by a one-off compen-sation payment (the "COMPENSATION
                                         PAYMENT"). The BENEFICIARY is only entitled to a compensation payment if CUREVAC
                                         exercises its right to make a compensation payment in accordance with Section 11 (1)
                                         sentence 1 within the term of the VAP.

 

		(2)	The
                                         calculation of the compensation payment is based on the principles outlined in

 

Appendix
5.

  

		(3)	In
                                         the event of capital increases from company funds or of any capital reduction or restructuring
                                         measures, without simultaneously meeting the requirements of the mer-ger exercise within
                                         the meaning of Section 9 (1), which took place after the signing of this contract and
                                         before the compensation payment, the BENEFICIARY's claim is to be corrected in accordance
                                         with paragraph (2). This correction ("adjustment") is based on the principles
                                         set out in Appendix 4.

  

		(4)	All
                                         claims of the BENEFICIARY arising in connection with or from this contract are fulfilled
                                         with the payment of the compensation payment. No other claims exist or arise in connection
                                         with or from this contract.

  

	Section
    12 	-	Information
    Rights of the Beneficiary

  

CUREVAC
shall immediately notify the BENEFICIARY of any exercise or impending exercise and other planned transactions that are
important for the exercise of the rights of the BENEFICIARY under this contract, unless and insofar as there are no compelling
confidentiality interests of CUREVAC or the third parties
involved in the ex-ercise or the transaction.

 

    14 

     

    

 

	Section
    13 	-	Term
    of this Contract

  

		(1)	The
                                         VAP ends on December 31, 2025; in the event of an IPO before December 31, 2025, it has
                                         a term until the end of the ninth calendar year after the date of the initial listing
                                         ("TERM OF THE VAP").

  

		(2)	Claims
                                         to shares in the revenue according to the provisions of this contract only exist if an
                                         exercise within the meaning of this contract occurs within the term of the VAP.

  

		(3)	This
                                         contract may be terminated by CUREVAC
                                         with immediate effect if the BENEFI-CIARY violates essential obligations from
                                         legal regulations, or violates this contract with respect to CUREVAC.
                                         In the event of this termination by CUREVAC,
                                         all PARTICI-PATION POINTS, including those that are already vested, shall be forfeited.

 

	Section
    14	-	Taxes,
    other Duties and Fees

  

		(1)	Taxes
                                         (including wage tax, church tax and solidarity surcharge) and other charges (e.g. employee
                                         contributions to pension insurance, unemployment insurance, health insurance and nursing
                                         care insurance), that are payable in connection with the partic-ipation of the BENEFICIARY
                                         in the VAP are to be paid internally only by the BENE-FICIARY or his legal successor.
                                         CUREVAC is
                                         entitled to withhold amounts owed ac-cordingly. In the case of the transfer of shares
                                         from the VAP, CUREVAC
                                         is entitled to sell the necessary number of shares in order to be able to withhold
                                         amounts owed under this paragraph.

  

		(2)	If
                                         this retention is not sufficient to repay the debt of taxes and duties of the type de-scribed,
                                         the BENEFICIARY is obliged to pay CUREVAC
                                         the amount missing to repay the entire debt of such taxes and other duties within
                                         three months of receiving a cor-responding request. Insofar as the tax office subsequently
                                         determines a higher wage tax base on the basis of an external audit or for other reasons,
                                         the BENEFICIARY is obliged to pay the additional taxes and other charges of the specified
                                         type to the tax office and the responsible social security institution as well as by
                                         way of a real contract in favor of third parties to exempt CUREVAC
                                         from its corresponding liability. The BEN-EFICIARY bears the corresponding tax
                                         risk.

  

    15 

     

    

 

		(3)	The
                                         BENEFICIARY is responsible for the tax review. CUREVAC
                                         assumes no liability for tax disadvantages and/or consequences that arise from
                                         the conclusion and/or im-plementation of this contract for the BENEFICIARY.

  

	Section
    15 	-	Payments

  

		(1)	Subject
                                         to the provision in Section 14, each payment to the BENEFICIARY under this contract is
                                         transferred to the last known account of the BENEFICIARY.

  

		(2)	To
                                         avoid misunderstandings: Payments to the beneficiaries under this contract will only
                                         be made , after an exercise has occurred and after the corresponding proceeds from the
                                         exercise have been paid to the respective shareholders of CUREVAC
                                         or CUREVAC
                                         itself and in the case of a compensation payment in accordance with Sec-tion 11.

  

		(3)	It
                                         is the understanding of the parties that the provision of paragraph (2) above also applies
                                         if the BENEFICIARY is entitled to vested PARTICIPATION POINTS after ter-mination of his
                                         service or employment and an exercise occurs after his employment ends. Section 11 remains
                                         unaffected.

 

	Section
    16 	-	Communications

  

The
BENEFICIARY undertakes to immediately inform CUREVAC
in writing of his ad-dress (postal address, telephone number, email address) and his account number (or, if available),
securities account details, and to inform CUREVAC immediately
in writing of changes to his address, name, account and securities account. All commu-nications from CUREVAC
to the BENEFICIARY are deemed to have been received on the third day after being sent to the address last communicated
to CUREVAC by the BENEFICIARY.

  

	Section
    17	-	Completeness
    of this Contract, Applicable Law, Court of Jurisdic-tion, Written Form

 

		(1)	This
                                         contract and letter of allocation contain all agreements that the parties have made regarding
                                         the VAP. There are no side agreements between the parties. Changes or additions to this
                                         contract must be in writing in order to be effective, unless notarial certification is
                                         required. This also applies to a waiver of the written form requirement.

  

    16 

     

    

 

		(2)	All
                                         appendices to this contract form an integral part of this contract.

  

		(3)	With
                                         the exception of international private law, this contract is subject to the law of the
                                         Federal Republic of Germany. The exclusive place of jurisdiction for all disputes aris-ing
                                         from or in connection with this contract is Tübingen.

  

	Section
    18 	-	Severability
    Clause

  

Should
one or more provisions of this contract prove ineffective, void or incomplete, the validity of the remaining provisions of the
contract remains unaffected. The parties will - if applicable in due form - replace the ineffective or void provision with such
a regulation or fill in the contractual gap with such a regulation with which the economic purpose pursued by them can best be
achieved. If the ineffectiveness or nullity of a provision is based on a measure of performance or time (deadline or date), then
a legally permissible measure should replace the ineffective or void performance or time determination.

 

			            
	(Place,
    date)	 	(Signature
    of BENEFICIARY)
	 	 	 
	 	 	 
	Tübingen,
    __________________________________________________	 	_______________________________________________
	 	 	CureVac
    AG

 

    17 

     

    

 

Appendix
1 

Beneficiary
Rights in the IPO Exercise Case

 

1.       Share
sale after IPO/further share sale after IPO

 

The
number of PARTICIPATION POINTS that can be exercised in each exercise case is calculated as follows:

 

	y
    (exercisable) = y	shares
    sold by majority shareholder
	 	total
    number of shares of majority shareholder at IPO

  

"y
(exercisable)" = corresponds to the number of PARTICIPATION POINTS that can be exercised in the respective exercise case
 "y" corresponds to the total number of PARTICIPATION POINTS granted to the BENE-FICIARY.

   

"Shares
sold by majority shareholder" corresponds to the number of shares sold by the main shareholder or his legal successors since
the time of the initial listing or since the last exercise of a share sale or further share sale, depending on which event is
later (without purchased shares since the IPO; the deduction may only be done once).

 

"Total
number of shares in majority shareholder at IPO" corresponds to the total number of shares held by the majority shareholder
or his legal successor at the time of the initial listing.

 

		2.	Exercise
                                         of drug approval after IPO

  

If
the exercise of drug approval occurs after the IPO, 100% of the PARTICIPATION POINTS of the BENEFICIARY can be exercised; only
a partial exercise of the PARTIC-IPATION POINTS by the BENEFICIARY is excluded.

 

		3.	Exercise
                                         of liquidity after IPO

  

Up
to 10% of the vested PARTICIPATION POINTS granted to the BENEFICIARY can be exercised in each 12-month period.

 

After
nine years after the initial listing, 100% of the remaining PARTICIPATION POINTS of the BENEFICIARY can be exercised; in this
case, only a partial exercise of the PAR-TICIPATION POINTS by the BENEFICIARY is excluded.

 

 

    18 

     

    

 

Appendix
2

 

Beneficiary
Rights in the Share Deal Exercise Case

 

The
amount of the share of the sales revenue that the BENEFICIARY can obtain due to his vested PARTICIPATION POINTS is calculated
with the liability capital unchanged or, if only one or more capital increases are made against contributions to CureVac, in case
of the exercise of the share deal according to the following formula:

 

	BENEFICIARY's
    claim =	y
    * Revenue SD
	 	StK
    (new) + x

  

"y"
is the number of PARTICIPATION POINTS of the BENEFICIARY vested before or during the exercise of the share deal;

  

"x"
is the total number of PARTICIPATION POINTS from the VAP 2013 and other compa-rable employee participation programs that were
vested in CureVac at the time the share deal is exercised.

  

"StK
(new)" is the amount of CureVac's liability capital at the time the share deal is exer-cised;

  

"Revenue
SD" is that of the shareholders of CureVac, who have sold shares in CureVac in the context of a share deal within the meaning
of Section 8, the sales revenue less the transaction costs and less all payments due to privileges of the holders of preferential
shares (e.g. preferential dividend, liquidation preference).

  

A
prerequisite for a participation of the BENEFICIARY in the revenue is that the consider-ation agreed for the purchase of shares
in CureVac, calculated on all shares in CureVac, is at least EUR 357,188,892.00.

 

    19 

     

    

 

Appendix
3

 

Beneficiary
Rights in the Merger/Asset Deal Exercise Case

 

The
amount of the share of the proceeds that the BENEFICIARY can demand due to his vested PARTICIPATION POINTS is calculated with
the liability capital unchanged or, if only one or more capital increases are made against contributions to CureVac, in case of
the exercise of the merger/asset deal according to the following formula:

 

	BENEFICIARY's
    claim =	y
    * Revenue M
	 	StK
    (new) + x

  

"y"
is the number of PARTICIPATION POINTS of the BENEFICIARY vested at the time the merger/asset deal is exercised;

  

"x"
is the number of PARTICIPATION POINTS from the VAP 2013 and other comparable employee participation programs that were vested
in CureVac at the time the merger/asset deal is exercised.

  

"StK
(new)" is the amount of CureVac's liability capital at the time the merger/asset deal is exercised;

  

"Revenue
M" is the value of the consideration that the shareholders of CureVac or CureVac itself receive in return, minus all payments
based on the privileges of the holders of preferential shares (e.g. preferential dividend, liquidation revenue) as well as minus
the transaction costs and the taxes paid or to be paid by CureVac.

  

The
entitlement to a share of the revenue is to be made in the form of cash or, if the consideration to CureVac consists in the granting
of shares in a company, in the payment of shares if these are admitted to trading on a domestic or foreign stock exchange.

  

A
prerequisite for a participation of the BENEFICIARY in the revenue is that the agreed consideration, calculated on all shares
in CureVac, is at least EUR 357,188,892.00.

   

    20 

     

    

   

Appendix
4

 

ADJUSTMENT

  

If
one of the following cases 1. and/or 2. occurs, the factors y and x of the formulae in Appendix 1 to 3 are to be corrected
according to the following formulae, which are used individually or in combination - if necessary, also multiple times:

  

		1.	For
                                         every capital increase from company funds as well as every capital reduction, if these
                                         took place before the exercise, the factors y and x of the formulae are to be corrected
                                         using the following formulae:

  

y
(new) = y * Amount of capital after corporate action 

Amount of capital after corporate action

  

x
(new) = x * Amount of capital after corporate action

 Amount of capital after corporate action

  

With
all the corrections following the first correction of the factors y and x, the result of the last correction takes the place of
the factors y and x in the calculation of y (new) and x (new) in the above formula.

  

"Amount
of capital after corporate action" is CureVac's liability capital figure following a capital increase from company funds
or a capital reduction;

  

"Amount
of capital before corporate action" is CureVac's liability capital figure before a capital increase from company funds or
a capital reduction.

  

		2.	For
                                         each restructuring before the exercise, the factors y and x of the formulae must be corrected
                                         using the following formulae:

  

y
(new) = y * _UW CureVac__*__ StK Target (new)__ 

(UW
CureVac + UW Target) * StK (new)

  

x
(new) = x * _UW CureVac__*__ StK Target (new)__ 

(UW
CureVac + UW Target) * StK (new)

 

    21 

     

    

  

With
all the corrections following the first correction of the factors y and x, the result of the last correction takes the place of
the factors y and x in the calculation of y (new) and x (new) in the above formula.

  

"Restructuring"
within the meaning of this subparagraph is a measure whereby, with-out the requirements of the merger/asset deal exercised in
accordance with Section 9 simultaneously being met, the shares in CureVac or more than 50% of the assets of CureVac are transferred
to a new independent company and the shareholders of CureVac are granted unlisted shares in this new legal entity. This is particularly
the case when the shares in CureVac or 50% or more of CureVac's assets are transferred in the context of (i) a merger within the
meaning of the Transformation Act as amended from time to time, (ii) a spin-off, (iii) a contribution to another company as a
contribution in kind or (iv) another economically comparable restructuring measure;

  

"UW
CureVac" is the corporate value of CureVac that will be used as the basis for the restructuring (exchange ratio);

 

"UW
Target" is the corporate value of the receiving legal entity that is used as the basis for the restructuring (exchange ratio);

 

"StK
Target (new)" is the liability capital of the receiving legal entity after the restruc-turing has been carried out;

 

"StK
(new)" is the amount of CureVac's liability capital immediately prior to the re-structuring.

  

In
the case of other restructuring measures that require a correction, also multiple correc-tions, in accordance with the above principles,
the correction must be carried out in ac-cordance with the principles of Section 4 of the Employee Participation Agreement. The
same applies to the granting of PARTICIPATION POINTS in later admission rounds, tak-ing into account the then existing liability
capital of CureVac and the scope of the VAP 2013 and other comparable employee participation programs.

  

    22 

     

    

 

Appendix
5

 

COMPENSATION
PAYMENT

  

The
proportion of the sales revenue that the BENEFICIARY can claim due to his vested PARTICIPATION POINTS in the event of a compensation
payment is calculated with un-changed liability capital or, if only one or more capital increases are made against contri-butions
to CureVac, using the following formula:

 

	BENEFICIARY's
    claim =	y
    * PMV           
	 	         StK
    (new) + x

  

"y"
is the number of PARTICIPATION POINTS of the BENEFICIARY vested at the time of the compensation payment;

  

"x"
is the number of PARTICIPATION POINTS from the VAP 2013 and other comparable employee participation programs that were vested
in CureVac at the time before the com-pensation payment.

  

"StK
(new)" is the amount of CureVac's liability capital at the time of the compensation payment;

  

"PMV"
is CureVac's post-money valuation (regarding 100% of the company's liability cap-ital) from the last round of financing that took
place before the BENEFICIARY's employ-ment ended. To avoid misunderstandings, the post-money valuation of CureVac is calcu-lated
using the following formula:

 

	PMV =  P * 100%
	
	Q

  

Wherein
the following applies:

  

		P	=
                                         payments on the registered liability capital including additional benefits in the capital
                                         reserves of CureVac within the meaning of Section 272 (2) HGB

  

    23 

     

    

 

		Q	=
                                         share of the registered liability capital of CureVac (in percent) after the financing
                                         round.

  

Example:

  

A
new investor subscribes to new shares in CureVac and brings in a total of EUR 10 million. After completing the financing round
(i.e. after the new shares have been reg-istered), the new investor holds 20% of the registered share capital in CureVac. Ac-cordingly,
the post-money valuation amounts to EUR 50 million.

  

    24Exhibit 10.30

 

REDACTED

Certain identified
information, indicated by [*****], has been
excluded from the exhibit because it

is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.

 

CONFIDENTIAL

EXECUTION VERSION

 

TERMINATION AGREEMENT

 

between

 

CUREVAC AG

 

and

 

ELI LILLY AND COMPANY

 

This TERMINATION AGREEMENT is effective as of June
26, 2020 (the “Termination Date”) and is entered into by and among:

 

CUREVAC AG,
a German corporation (“CureVac AG”), having a place of business at Friedrich-Miescher-Strasse 15, 72076 Tübingen,
Germany;

 

CUREVAC REAL ESTATE GMBH, a German limited liability
company, having a place of business at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany (CureVac AG and CureVac Real
Estate GmbH jointly “CureVac”) and

 

ELI LILLY AND COMPANY,
an Indiana corporation (“Lilly”), having a place of business at Lilly Corporate Center, Indianapolis, Indiana
46285.

 

INTRODUCTION

 

A.               WHEREAS,
CureVac AG and Lilly are parties to that certain License and Collaboration Agreement effective as of November 29, 2017 (“License
Agreement”), and CureVac Real Estate GmbH and Lilly are parties to that certain Early Clinical Supply Agreement dated
July 5, 2018, and related Quality Agreement dated June 29, 2018 (“Supply and Quality Agreements”);

 

B.                WHEREAS,
Lilly has informed CureVac that it intends to terminate the License Agreement in accordance with Section 11.2 (Termination at
Will by Lilly), unless the Parties agree to mutually terminate the License Agreement.

 

    	 	 	1

     

    

 

CONFIDENTIAL

EXECUTION VERSION

 

C.               WHEREAS, CureVac
and Lilly are interested in an early termination of the License Agreement and the Supply and Quality Agreements, and an agreement
on the consequences of such termination which will allow CureVac to continue the Development Program (as defined in the License
Agreement), and Lilly to reevaluate the program after completion of the first Phase I Study.

 

NOW THEREFORE, in consideration of the
foregoing premises and the following mutual covenants, agreements and stipulations set forth herein, the receipt and sufficiency
of which is hereby acknowledged, the Parties agree as follows:

 

Article I – Definitions

 

All capitalized terms used in this Termination
Agreement shall have the meaning as defined in the License Agreement, unless otherwise defined herein. In case of conflict or inconsistency
between the provisions of the Termination Agreement and any surviving provision of the License Agreement, the provisions of this
Termination Agreement shall prevail.

 

Article II – Termination

 

	2.1	The Parties hereby agree that the License Agreement and the Supply and Quality Agreements terminate
on the Termination Date. Consistent with Section 11.4(c)(i), as of the Termination Date, all rights licensed to Lilly under the
License Agreement, including the rights to the CureVac Intellectual Property automatically revert back to CureVac AG, and CureVac
shall be free to use, license and transfer these rights.

 

	2.2	The Parties agree that, subject only to the rights and obligations under this Termination Agreement,
and with the exception of Section 11.6 of the License Agreement (Accrued and Surviving Obligations), all rights and obligations
under the License Agreement and Supply and Quality Agreements terminate as of the Termination Date, and neither Lilly nor CureVac
have any further claims under the License Agreement or the Supply and Quality Agreements; provided, that, notwithstanding anything
to the contrary in the License Agreement, the Parties acknowledge and agree that with respect to the survival of Section 11.4,
only Sections 11.4(a), 11.4(c)(i), 11.4(c)(v) and 11.4(e) shall survive; and (ii) Section 13.4 of the Early Clinical Supply Agreement
referred to in the INTRODUCTION above shall be of no further force or effect and Lilly has no liability in connection any unused
capacity.

 

Article III – Transfers and Support

 

	3.1	Development
                                         Data. Within [*****] of
                                         the Termination Date, Lilly shall provide access to CureVac to [*****] developed
                                         under the Development Program, and all [*****],
                                         and that are both (i) in Lilly’s or its Affiliates’ possession and control,
                                         and (ii) set forth on Exhibit 3.1 hereto. The Parties acknowledge and agree that
                                         the items set forth on Exhibit 3.1 hereto are [*****] of
                                         the [*****] work
                                         performed by Lilly under the License Agreement. Upon CureVac’s
                                         reasonable request, Lilly may provide support to CureVac through employees, for up to
                                         a total of [*****] of personnel time, to reasonably support CureVac in the preparation
                                         of the IND for the Initial Product.

 

 

    	 	 	2

     

    

 

CONFIDENTIAL

EXECUTION
VERSION

 

	3.2	Intellectual Property. Lilly shall reassign and
                                                                            retransfer, and hereby reassigns and retransfers to CureVac AG the composition of matter patent titled [*****],  and any
                                                                            Patents based thereon [*****], which had been assigned and transferred from CureVac AG to Lilly under the License Agreement,
                                                                            provided such Patents have not been withdrawn or abandoned in accordance with CureVac’s instructions. CureVac hereby
                                                                            accepts the reassignment and retransfer. Lilly shall execute and deliver all such documents, instruments and other papers and
                                                                            take all such other action which CureVac may reasonably request in order to effect the assignment and transfer; provided,
                                                                            that any reasonable and documented costs and expenses that Lilly incurs in connection with providing such assistance beyond
                                                                            executing an initial assignment of such patent shall be reimbursed by CureVac in accordance with payment terms to be
                                                                            reasonably agreed by the Parties in good faith. CureVac shall have the sole authority to enforce and defend the reassigned
                                                                            and retransferred [*****] composition of matter patent described above, at CureVac’s sole cost and expense. As of the
                                                                            Effective Date of this Termination Agreement, Lilly represents that, to the actual knowledge of those specific individuals
                                                                            involved in negotiating this Termination Agreement on behalf of Lilly, it has not [*****] – and none of its
                                                                            Affiliates have [*****] - [*****]. CureVac shall retain the right to demand from Lilly solely (without any further obligation
                                                                            to Lilly) the license under Section 11.4 (c)(ii)(y) of the License Agreement, provided, however, that CureVac may exercise
                                                                            such right at any time within [*****] after the Termination Date.

 

	3.3	Material. Within
                                                                                                                                          [*****] of the Termination Date, Lilly shall transfer [*****] and [*****] all [*****]  produced under the
                                                                                                                                          License Agreement or the Supply and Quality Agreements (collectively, “Materials”),  and that are
                                                                                                                                          both (i) controlled by Lilly and (ii) in stock with Lilly or with a Third Party CMO on the Termination Date, including but
                                                                                                                                          not limited to [*****]. All Materials are transferred “as-is” with no representations or warranties and CureVac
                                                                                                                                          assumes full liability for any use or disposition of the Materials.

 

	3.4	Consideration.  In
                                                                                                                                   consideration, in part, for the transfers under Sections 3.1 to 3.3, CureVac agrees that Lilly
                                                                                                                                   will have no further cost liabilities under the License Agreement or Supply [*****] and commercial work, including wind-down
                                                                                                                                   fees, if any.

 

    	 	 	3

     

    

 

CONFIDENTIAL

EXECUTION VERSION

 

Article IV – Right of First Negotiation

 

	4.1	In
the event CureVac, its Affiliate or sublicensee conduct and complete a [*****] of the Initial Product, CureVac, its Affiliate
or sublicensee, will grant Lilly a right of first negotiation with respect to the  
Initial Product, to be exercised within [*****] after completion [*****]
of such [*****].

 

	4.2	For
                                         such purpose, CureVac, its Affiliate or sublicensee, will make available to Lilly within
                                         [*****] after completion of such [*****] a data package containing the final study report
                                         and additional data  and
                                         documentation that Lilly may timely request, which may be reasonably required to evaluate
                                         the results   of
                                         such [*****].

 

	4.3	Within
[*****] after receipt of both (to the extent applicable) the data package and any additional data or documentation that Lilly
requests under Section 4.2 (i.e., within a maximum of [*****]),  Lilly
will inform CureVac AG, its Affiliate or sublicensee, whether Lilly is interested in negotiating an   exclusive
license to further develop, manufacture and commercialize the Initial Product at reasonable terms  and conditions, reflecting
[*****]. The terms and  conditions of such license agreement
will be negotiated within a term of another [*****] after notice by Lilly of its interest. For the avoidance of doubt, if Lilly
is not interested in obtaining a license to the Initial Product, if it does not express its interest within [*****] after completion
of the [*****], or if Lilly and CureVac AG, its Affiliate or sublicensee are not able to agree on the terms of such  
license within such additional [*****] period, all obligations under
this Article 4 terminate, and  CureVac, its Affiliate or
sublicensee will be free to continue the development and/or grant rights to the Initial Product to any Third Party.

 

Article V – Confidentiality

 

	5.1	This Termination Agreement shall be considered Confidential Information of both Parties and the
disclosure of such Confidential Information requires the prior written consent of the other Party, such consent not to be unreasonably
withheld, delayed or conditioned.

 

	5.2	Notwithstanding Section 5.1, CureVac is entitled to approach Third Parties regarding a potential
license with respect to the Initial Product, and the license or transfer of the intellectual property, development data and material
which is transferred to CureVac under Article III above; provided, that any such license - if granted prior to the expiry of Lilly’s
right of first negotiation under Article IV - shall be subject to Lilly’s right of first negotiation under Article IV. CureVac
may inform such Third Party that the License Agreement has been terminated, and that CureVac has reacquired such rights and is
free to license such rights to a Third Party subject to Lilly’s right of first negotiation under Article IV.

 

    	 	 	4

     

    

 

CONFIDENTIAL

EXECUTION VERSION

 

Article VI – Miscellaneous

 

In addition to the specific section or
article references contained herein, Section 10.7 (Limitations), Article IX (Confidentiality) and Article XII (Miscellaneous) of
the License Agreement shall apply, mutatis mutandis, to this Termination Agreement.

 

[Signature Page Follows]

 

    	 	 	5

     

    

 

CONFIDENTIAL

EXECUTION VERSION

 

IN WITNESS WHEREOF, this Termination Agreement has been signed
by the Parties hereto in two (2) originals, each Party acknowledging receipt of one original.

 

 

	 Signed on
behalf of	)	 	 
	CureVac AG	)	 	 
	 	)	 	 
	 	)	 	 
	Signature of Authorized Officer:	 	/s/ Dr. Franz-Werner Haas	 	/s/ Pierre Kemula

 

	 	 	 	 
	Name of Authorized Officer (please print):	 	Dr. Franz-Werner
Haas, Acting CEO & Pierre Kemula, CFO	 

 

	Date Signed:	 	June 26, 2020	 

 

 

	 Signed on
behalf of	)	 	 
	CureVac Real Estate GmbH	)	 	 
	 	)	 	 
	 	)	 	 
	Signature of Authorized Officer:	 	/s/ Dr. Florian von der Mülbe, CPO	 

 

	Name of Authorized Officer (please print):	 	 Dr. Florian von der
Mülbe, CPO	 

 

	Date Signed:	 	June 26, 2020	 

 

	 Signed on
behalf of	)	 	 
	Eli Lilly and Company	)	 	 
	 	)	 	 
	 	)	 	 
	Signature of Authorized Officer:	 	/s/ Daniel Skovronsky	 

 

	Name of Authorized Officer (please print):	 	 Daniel Skovronsky	 

 

	Date Signed:	 	06/29/2020	 

 

    	 	 	6

     

    

 

CONFIDENTIAL

EXECUTION VERSION

 

Exhibit 3.1

Written
Materials

 

 

[*****]

 

    	 	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]